US BIS: Australia Group 2021–2022 Decisions — Marine Toxin, Plant Pathogen, and Biological Equipment EAR Updates

Mechanism

The Australia Group is a multilateral export control arrangement of ~43 member states focused on preventing the spread of chemical and biological weapons (CBW) precursors, agents, and related equipment. Member states harmonize their national export controls with the AG Common Control Lists through periodic Implementation Meetings and an annual Plenary.

This BIS final rule implements three sets of decisions:

1 — Marine toxins added to ECCN 1C351.d

Four marine biotoxins are added to the "Human and Animal Pathogens and Toxins" list, controlled for CB (chemical-biological weapons) and AT (anti-terrorism) reasons:

Simultaneously, cholera toxin is removed from 1C351.d on the grounds that its widespread use in legitimate biomedical research (as an adjuvant and cell-biology probe) and its relatively low cytotoxicity compared to other listed toxins make continued control disproportionate.

2 — Plant pathogen nomenclature updates (1C354)

The organisms were already controlled; BIS updates the scientific names to align with current taxonomy. No new substances added:

• Xanthomonas axonopodis pv. citri → Xanthomonas citri pv. citri
• Clavibacter michiganensis subsp. sepedonicus (nomenclature clarified)
• Cochliobolus miyabeanus → Bipolaris oryzae
• Microcyclus ulei → Pseudocercospora ulei

3 — Biological equipment clarifications (ECCN 2B352)

• Revised definition of "disinfected": now means a process that reduces microorganisms

to a level not normally capable of producing infection in healthy humans but does not typically eliminate bacterial spores. This separates "disinfected" from "sterilised" more precisely.

• Clarified medical isolator exclusions: equipment used primarily in healthcare settings

(patient isolation rather than containment of biological agents) is excluded from 2B352 scope, reducing over-classification of routine medical devices.

Downstream implications

• Exporters of marine biotoxins (research supply chains, biotech, marine-natural-product

industries) must now apply for licences or confirm applicable licence exceptions (e.g., License Exception STA for AG-member destinations) before shipping brevetoxins, gonyautoxins, nodularins, or palytoxin.

• Life-science suppliers shipping to non-CWC-party destinations face the tightest restrictions;

CWC parties in good standing remain eligible for streamlined treatment.

• Cholera-toxin exporters gain regulatory relief — the substance drops off ECCN 1C351.d and

returns to EAR99 territory for most end-uses.

• Taxonomy-update-only changes to 1C354 impose no new licensing burden but require compliance

teams to update product classifications to reflect current species names.

Open questions

• The AG has continued to meet since 2022; any 2023 or 2024 plenary decisions will require a

further BIS rulemaking (see also 2024-12-23-us-bis-australia-group-implementation-2023-2024-plenary).

• Palytoxin is commercially produced for research use; watch for guidance on de minimis

concentrations or research-quantity exclusions.